By Anna C. Greene, PhD, NETRF Chief Scientific Officer
At the Neuroendocrine Tumor Research Foundation (NETRF), we fund research that can change how neuroendocrine cancers are understood, diagnosed, and treated. A newly published study, Characterization of Small Intestinal Neuroendocrine Tumorlets, offers exactly that kind of insight. The study was led by Eric Nakakura, MD, PhD, and colleagues at the University of California, San Francisco. It builds on genomic research supported through a NETRF Accelerator Award focused on uncovering the causes of small intestinal neuroendocrine tumors (SI-NETs).
SI-NETs are known for an unusual feature: many patients develop multiple primary tumors in the intestine, known as multifocal disease, while others appear to have just a single tumor, called unifocal disease. Surgeons carefully examine the small intestine, especially the jejunum and ileum, during surgery to find visible tumors, but this study suggests there may be another layer of disease that cannot be seen or felt.
Researchers identified microscopic neuroendocrine tumor clusters in the superficial layers of the small intestine. They named these lesions small intestinal neuroendocrine tumorlets, or SINTs. These tumorlets were tiny, often less than a tenth of a millimeter, and were found in both multifocal and unifocal SI-NET cases. In the study, SINTs were detected in 50% of multifocal cases and 30% of unifocal cases.
Unifocal vs. Multifocal Disease
This finding challenges the traditional distinction between “unifocal” and “multifocal” disease. Some patients who appear to have only one tumor may, in fact, have microscopic lesions that place them on a broader multifocal spectrum.
“By looking very carefully under the microscope, we found tiny neuroendocrine lesions near visible small intestinal NETs,” said Eric Nakakura, the study’s corresponding author. “These tumorlets were present in about half of multifocal cases and one-third of cases that appeared to have only one tumor. This suggests multifocality may be a more common feature of SI-NETs than previously recognized. Our findings point to a new way of thinking about how these tumors begin, spread, and progress.”
Importantly, patients with either multifocal tumors or microscopic tumorlets showed signs of more locally aggressive disease, including tumor growth around nearby nerves, larger mesenteric masses, and more advanced local tumor stage. However, the study did not find a clear difference in progression-free survival, so larger studies will be needed to understand whether SINTs can help predict long-term outcomes.
The study also raises a compelling biological question: could some tumorlets help seed new tumors? Genomic re-analysis found that some tumors within the same patient shared rare genetic variants, suggesting that a subset of tumor cells may have a common ancestral origin. In other words, at least some SI-NETs that appear separate may be connected through local spread.
The researchers also observed some SINTs within lymphatic vessels, offering a possible route for local spread along the intestine. This may help explain why SI-NETs so often appear as multiple tumors and why the true frequency of multifocal disease may be higher than currently recognized.
New Questions This Study Raises
For patients, this work is still early and does not yet change clinical care. But it opens important new questions:
- Could SINTs become a biomarker of local aggressiveness?
- Should pathology review look more carefully for these microscopic lesions?
- Could understanding tumorlets improve how clinicians assess recurrence risk or surgical margins?
As the authors note, larger studies are needed to validate the prognostic and biological significance of SINTs. Still, this research reveals a hidden layer of SI-NET biology and points toward a more nuanced view of the disease, one that sees not just visible tumors, but the microscopic ecosystems that may shape how tumors develop and spread.
At NETRF, this is why we invest in discovery science. By supporting research that uncovers the earliest and least visible features of neuroendocrine tumors, we move closer to better detection, more precise care, and improved outcomes for patients.
________________________________________________________________________________________________________________________________________________________